Stage I testicular seminoma: rationale for postorchiectomy radiation therapy

Abstract

The cases of 163 patients with Stage I seminoma of the testis treated by orchiectomy and adjuvant radiation therapy (XRT) were retrospectively evaluated to document outcome and to determine the prognostic significance of age side or primary, cryptorchidism, prior ipsilateral herniorrhaphy, status of the contralateral testis, history of prior testicular cancer, scrotal incision, postorchiectomy beta- human chorionic gonadotropin (BHCG) level, invasion of the epididymis, spermatic cord involvement, vascular invasion in the primary and mediastinal XRT. Of the prognostic factors evaluated, only spermatic cord involvement proved to be a significantly adverse factor. However, the true significance of cord involvement is unclear because the para-aortic regions were not irradiated in 2 of the patients in whom there was this finding, and in 1 of these there was failure in the retroperitoneum. Spermatic cord involvement was not a prognostically significant finding in patients whose para-aortic region was treated. For all 163 patients who underwent XRT, disease-free survival was 95% at 5, 10, and 15 years. Total survival corrected for intercurrent death was 97% from 5 through 20 years. Seven patients relapsed (4%) and 4 died of seminoma (2%). The XRT technique described is simple to implement and is extremely effective. Of 161 patients whose para-aortic region was irradiated, none developed subdiaphragmatic nodal recurrence. Only 1 patient developed acute leukemia. No patient developed any of the recognized delayed XRT-induced complications involving small bowel, large bowel, bladder, kidney, liver or spinal cord. The virtues and limitations of surveillance in Stage I testicular seminoma are discussed, and it is concluded that routine postorchiectomy XRT is the treatment of choice.